News

The European Lead Factory (ELF) project has some impressive numbers to share! Over the past months, ELF Partner BioAscent has shipped 3,256 screening plates from the updated Compound Collection to the nine screening sites that are part of ELF.

Together with the European Lead Factory (ELF), scientists from the German Cancer Research Center (DKFZ) have successfully discovered potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

This 30 January marks the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative designed to draw attention to priority issues surrounding NTDs and the efforts being made to combat them.

Pivot Park Screening Centre (PPSC) is excited to announce the availability of a novel technology for screening in European Lead Factory.

The European Lead Factory is excited to continue running high quality programmes and is looking forward to receiving more innovative screening proposals.

2 May 2019, Utrecht (The Netherlands) The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI).

The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI).

The European Lead Factory has successfully accelerated the process of drug discovery. A recently published public summary of results so far clearly shows the benefits of collaborative drug discovery in the European arena.

Yesterday the European Lead Factory animation won the best Innovative Medicines Initiative (IMI) Communication Product Award. The awards were handed out as part of IMI’s 10th anniversary during the IMI Scientific Symposium in Brussels.

Keapstone Therapeutics is preparing to make the next steps in clinical candidate selection and first-in-human studies. This investment brings the total seed investment to € 2,4 million.

The key goal of ELF is to create validated hit series. Another successful ELF programme aimed at identifying small molecules for the treatment of Alzheimer’s Disease has culminated in the most potent compound yet identified by the ELF team at Newhouse, Scotland with the most active compound reaching 100pM. These compounds also have excellent physicochemical properties.

The European Lead Factory is remarkably attractive for SMEs. The consortium consists of 30 partners, of which 10 are SMEs. They perform the screening and help to translate innovative design ideas into industry‐standard compound libraries.

Within a period of five years, the European Lead Factory (ELF) has reached one of its goals by completing the Public Compound Collection (PCC), comprising a commendable total of 200,000 novel compounds. The library production partners collaborated closely with the academic groups within ELF to reach this goal.

On 16 and 17 April 2018 the European Lead Factory (ELF) Target Owner Workshop and Stakeholder Meeting took place in the heart of Europe, Brussels. An exciting row of speakers allowed for a retrospect on five years of successfully seeding and nursing innovative drug discovery projects.

On April 19, Prof Adam Nelson, University of Leeds, won the UCB-Ehrlich Award for Excellence in Medicinal Chemistry. This award was established to acknowledge and recognise outstanding research in the field of Medicinal Chemistry, and is the most prestigious prize an academic medicinal chemist can get.